​

Avadel Pharmaceuticals Stock (NASDAQ:AVDL)

ForecastRevenueOwnershipFinancialsChartTranscripts
Avadel Pharmaceuticals by TradingView

Previous Close

$21.64

52W Range

$6.38 - $23.57

50D Avg

$21.50

200D Avg

$15.49

Market Cap

$2.12B

Avg Vol (3M)

$2.42M

Beta

1.31

Div Yield

-

AVDL Company Profile

Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

IE

Employees

188

IPO Date

Jun 07, 1996

Website

AVDL Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 20
Reportable Segment$169.12M-
Akovaz-$9.54M
Bloxiverz-$2.20M
License--
Other Products-$159.00K
Vazculep-$10.43M

Fiscal year ends in Dec 24 | Currency in USD

AVDL Financial Summary

Dec 24Dec 23Dec 22
Revenue$169.12M$27.96M-
Operating Income$-42.40M$-137.85M$-98.56M
Net Income$-48.83M$-160.28M$-137.46M
EBITDA$-42.40M$-149.13M$-97.60M
Basic EPS$-0.51$-2.00$-2.29
Diluted EPS$-0.51$-2.00$-2.29

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q2 25Aug 08, 25 | 8:30 AM
Q1 25May 07, 25 | 9:00 AM
Q4 24Mar 03, 25 | 8:30 AM

Peer Comparison

TickerCompany
OGNOrganon & Co.
TLRYTilray Brands, Inc.
BGMBGM Group Ltd.
EVOEvotec SE
QDELQuidelOrtho Corporation
ANIPANI Pharmaceuticals, Inc.
MDPediatrix Medical Group, Inc.
GRDNGuardian Pharmacy Services, Inc.
PAHCPhibro Animal Health Corporation
ALVOAlvotech